{"fetched":"2026-10-15","feeds":[{"id":"fda-oce","name":"FDA Oncology Center of Excellence","homepage":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","kind":"regulator","sourceId":"fda-approvals","ok":true,"count":11},{"id":"nejm","name":"New England Journal of Medicine","homepage":"https://www.nejm.org/","url":"https://www.nejm.org/action/showFeed?type=etoc&feed=rss&jc=nejm","kind":"journal","sourceId":"nejm","onlyOncology":true,"ok":true,"count":5},{"id":"lancet-oncology","name":"The Lancet Oncology","homepage":"https://www.thelancet.com/journals/lanonc/home","url":"https://www.thelancet.com/rssfeed/lanonc_current.xml","kind":"journal","sourceId":"lancet-oncology","ok":true,"count":40},{"id":"jco","name":"Journal of Clinical Oncology","homepage":"https://ascopubs.org/journal/jco","url":"https://ascopubs.org/action/showFeed?type=etoc&feed=rss&jc=jco","kind":"journal","sourceId":"jco","ok":true,"count":40},{"id":"nature-medicine","name":"Nature Medicine","homepage":"https://www.nature.com/nm/","url":"https://www.nature.com/nm.rss","kind":"journal","sourceId":"nature-medicine","onlyOncology":true,"ok":true,"count":4},{"id":"endpoints","name":"Endpoints News","homepage":"https://endpts.com/","url":"https://endpts.com/feed/","kind":"news","sourceId":"src-endpoints-news","onlyOncology":true,"ok":true,"count":3},{"id":"stat","name":"STAT","homepage":"https://www.statnews.com/","url":"https://www.statnews.com/feed/","kind":"news","sourceId":"src-stat-news","onlyOncology":true,"ok":true,"count":1}],"items":[{"feedId":"fda-oce","title":"FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle","date":"2026-10-14","refs":["nogapendekin-alfa","immunitybio","urothelial","non-muscle-invasive-bladder-cancer","beone","alfa"]},{"feedId":"nature-medicine","title":"Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial","url":"https://www.nature.com/articles/s41591-026-04717-8","date":"2026-10-14","refs":["ovarian","nct07218003","nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690"]},{"feedId":"nature-medicine","title":"Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial","url":"https://www.nature.com/articles/s41591-026-04671-5","date":"2026-10-14","refs":["prostate","enzalutamide","talazoparib","nct07106762"]},{"feedId":"endpoints","title":"Verastem makes its stand as a RevMed competitor in pancreatic cancer","url":"https://endpoints.news/verastem-makes-its-stand-as-a-revmed-competitor-in-pancreatic-cancer/","date":"2026-10-14","refs":["pancreatic","nct07353645","verastem","kras-inhibitors","kras"]},{"feedId":"endpoints","title":"Vir makes solid tumor T cell engager deal with Gilead","url":"https://endpoints.news/vir-makes-solid-tumor-t-cell-engager-deal-with-gilead/","date":"2026-10-14","refs":[]},{"feedId":"stat","title":"STAT+: FDA adcomm members’ ties to industry under scrutiny","url":"https://www.statnews.com/2026/10/14/biotech-news-fda-adcomm-member-ties-to-industry-under-scrutiny/?utm_campaign=rss","date":"2026-10-14","refs":[]},{"feedId":"jco","title":"The Boy Who Became a Tiger","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00001","date":"2026-10-13","refs":[]},{"feedId":"nature-medicine","title":"Characterizing the onset and progression of cancer cachexia using routine clinical data","url":"https://www.nature.com/articles/s41591-026-04720-z","date":"2026-10-13","refs":[]},{"feedId":"endpoints","title":"BioNTech’s head and neck cancer vaccine misses first of two goals","url":"https://endpoints.news/biontechs-head-and-neck-cancer-vaccine-misses-first-of-two-goals/","date":"2026-10-13","refs":["biontech"]},{"feedId":"jco","title":"Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer—The Copenhagen Lung Cancer Risk Model (CPH-Lung)","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02326","date":"2026-10-12","refs":["lung-cancer"]},{"feedId":"nature-medicine","title":"A health-system-scale, episode-resolved multimodal atlas of cancer cachexia","url":"https://www.nature.com/articles/s41591-026-04689-9","date":"2026-10-12","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02995","date":"2026-10-09","refs":["prostate-mcrpc","androgen-receptor","prostate","nct02802423","nct06861452","nct06149481","nct07063329","nct06110572"]},{"feedId":"fda-oce","title":"FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer","date":"2026-10-08","refs":["mmr","nct04434040","nct07381309","atezolizumab","colon-cancer","nct06782685","oxaliplatin","roche-genentech"]},{"feedId":"jco","title":"RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00725","date":"2026-10-08","refs":["varegacestat","nct05744687","nct04871282","nct07290088"]},{"feedId":"jco","title":"Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00742","date":"2026-10-08","refs":["neuroblastoma"]},{"feedId":"fda-oce","title":"FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer","date":"2026-10-07","refs":["breast-her2-positive","breast-cancer","trastuzumab","nct06891833","pertuzumab","nct04514419","tucatinib","nct05035745"]},{"feedId":"nejm","title":"Advances in Systemic Treatment of Breast Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMra2500695?af=R&rss=currentIssue","date":"2026-10-07","refs":["breast-cancer"]},{"feedId":"jco","title":"NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00201","date":"2026-10-07","refs":["breast-cancer","nct05744687","nct07290088"]},{"feedId":"jco","title":"Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00670","date":"2026-10-06","refs":[]},{"feedId":"fda-oce","title":"FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic","date":"2026-10-02","refs":["apex-03","nct06943872","nct02966756","nct06588478","nct05023980","nct05254743","nct04965493","pirtobrutinib"]},{"feedId":"jco","title":"Clinical Practice Guideline for Systemic Antibacterial and Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Cell Transplant Recipients: 2026 Update","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00720","date":"2026-10-02","refs":[]},{"feedId":"lancet-oncology","title":"[Editorial] Microplastics and cancer: a looming threat?","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00483-3/fulltext","date":"2026-10-01","refs":["lung-cancer","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Looking at cancer burden in Africa through a new lens","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00381-5/fulltext","date":"2026-10-01","refs":["nct06936774","nct07257653","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Blank spaces on the map: genomics for global cancer research","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00460-2/fulltext","date":"2026-10-01","refs":[]},{"feedId":"lancet-oncology","title":"[Comment] England's National Cancer Plan; ambition without accountability","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00458-4/fulltext","date":"2026-10-01","refs":[]},{"feedId":"lancet-oncology","title":"[Correspondence] Re-evaluating aglatimagene in localised prostate cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00356-6/fulltext","date":"2026-10-01","refs":["aglatimagene-besadenovec","aurora","prostate","t-cell-histiocyte-rich-large-b-cell-lymphoma"]},{"feedId":"lancet-oncology","title":"[Correspondence] Re-evaluating aglatimagene in localised prostate cancer – Authors' reply","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00462-6/fulltext","date":"2026-10-01","refs":["prostate"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00344-X/fulltext","date":"2026-10-01","refs":["stage-iii-unresectable-nsclc","nsclc","sclc","lung-cancer","durvalumab","pacific","nct07221474"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00397-9/fulltext","date":"2026-10-01","refs":["durvalumab","pacific","nct07221474"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00402-X/fulltext","date":"2026-10-01","refs":["stage-iii-unresectable-nsclc","nsclc","sclc","lung-cancer","durvalumab","pacific","nct07221474","nct06745882"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00444-4/fulltext","date":"2026-10-01","refs":["durvalumab","pacific","nct07221474"]},{"feedId":"lancet-oncology","title":"[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC – Authors' reply","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00475-4/fulltext","date":"2026-10-01","refs":["durvalumab","pacific"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 1043–56","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00484-5/fulltext","date":"2026-10-01","refs":["stage-iii-unresectable-nsclc","nsclc","sclc","lung-cancer","nct05035745","nct05281471","nct06463665","nct06590246"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 1077–93","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00472-9/fulltext","date":"2026-10-01","refs":["tace","hcc","tremelimumab","lenvatinib","nct04875585","durvalumab","emerald-3","emerald"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 1094–109","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00473-0/fulltext","date":"2026-10-01","refs":["egfr-mutant-nsclc","nsclc","sclc","nct07381309","ivonescimab","lung-cancer","nct05035745","nct06590246"]},{"feedId":"lancet-oncology","title":"[Perspectives] Cancer's new anxiety: not a death sentence, but delay","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00476-6/fulltext","date":"2026-10-01","refs":[]},{"feedId":"lancet-oncology","title":"[Perspectives] Against cancer, not against dying: Ernest Becker in the oncology clinic","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00477-8/fulltext","date":"2026-10-01","refs":["colorectal"]},{"feedId":"lancet-oncology","title":"[Perspectives] Differing approaches to cancer at the Edinburgh Fringe","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00478-X/fulltext","date":"2026-10-01","refs":["chordoma"]},{"feedId":"lancet-oncology","title":"[Articles] Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00307-4/fulltext","date":"2026-10-01","refs":["hpv-vaccine","anal","anchor"]},{"feedId":"lancet-oncology","title":"[Articles] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00297-4/fulltext","date":"2026-10-01","refs":["breast-cancer","nct06949111"]},{"feedId":"jco","title":"Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00247","date":"2026-09-30","refs":[]},{"feedId":"jco","title":"Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01114","date":"2026-09-29","refs":["sentinel-node","breast-cancer","nct07381309","nct05562297","nct07412613","nct05035745","nct06590246"]},{"feedId":"jco","title":"Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00735","date":"2026-09-29","refs":["brca"]},{"feedId":"lancet-oncology","title":"[Comment] Personalised medicine in oncology: inequality aversion in a fast-moving field","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00435-3/fulltext","date":"2026-09-25","refs":["cancer-of-unknown-primary","companion-diagnostic","a16z-bio-health","state-arc"]},{"feedId":"lancet-oncology","title":"[Comment] Ethical priorities in global cancer genomics and precision oncology","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00442-0/fulltext","date":"2026-09-25","refs":["a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Inequities in access to precision oncology: shared challenges, unified blueprint","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00448-1/fulltext","date":"2026-09-25","refs":["nct06936774","toshiba-energy-systems","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Beyond the evidence: why multistakeholder cooperation will determine whether cancer genomics reaches patients","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00437-7/fulltext","date":"2026-09-25","refs":[]},{"feedId":"lancet-oncology","title":"[Comment] Ecological neglect: critical oversight in precision oncology governance","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00407-9/fulltext","date":"2026-09-25","refs":["gvhd-belumosudil-axatilimab-ibrutinib","nct05035745","nct06590246","a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] Affordability in the era of precision oncology","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00436-5/fulltext","date":"2026-09-25","refs":["nct05281471","nct06463665","a16z-bio-health","gdf7"]},{"feedId":"lancet-oncology","title":"[Comment] Counting who was not tested: artificial intelligence extraction of genomic and treatment data from hospital records","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00449-3/fulltext","date":"2026-09-25","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00401","date":"2026-09-25","refs":["multiple-myeloma","dexamethasone","lenalidomide","daratumumab","bortezomib","cepheus"]},{"feedId":"fda-oce","title":"FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component","date":"2026-09-24","refs":["rcc","lenvatinib","nct04875585","belzutifan","nct04924075","nct05035745","nct06590246","eisai"]},{"feedId":"nejm","title":"IARC Perspective on Lung Cancer Screening","url":"https://www.nejm.org/doi/full/10.1056/NEJMsb2608211?af=R&rss=currentIssue","date":"2026-09-24","refs":["lung-cancer"]},{"feedId":"jco","title":"First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02933","date":"2026-09-24","refs":["egf","retlirafusp-alfa","urethral-adenocarcinoma","lung-adenocarcinoma","nct07381309","gastric","gdf7","alfa"]},{"feedId":"fda-oce","title":"FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic","date":"2026-09-23","refs":["elevar-therapeutics","lirafugratinib","nct05035745","nct06590246","gdf7","fgfr2","beone"]},{"feedId":"jco","title":"Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00017","date":"2026-09-23","refs":["cholangiocarcinoma","biliary-tract-cancer","ascot-jcog1202","scot"]},{"feedId":"nejm","title":"Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2505723?af=R&rss=currentIssue","date":"2026-09-22","refs":[]},{"feedId":"nejm","title":"A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMe2611312?af=R&rss=currentIssue","date":"2026-09-22","refs":["grail"]},{"feedId":"jco","title":"When Survival Separates","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00371","date":"2026-09-22","refs":[]},{"feedId":"jco","title":"Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02766","date":"2026-09-22","refs":["melanoma","braf"]},{"feedId":"jco","title":"Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02476","date":"2026-09-21","refs":["ductal-carcinoma-in-situ"]},{"feedId":"fda-oce","title":"FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or","date":"2026-09-18","refs":["breast-hr-positive","nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886"]},{"feedId":"jco","title":"Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02737","date":"2026-09-18","refs":["a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[News] 2026 World Conference on Lung Cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00480-8/fulltext","date":"2026-09-17","refs":["adc","sclc","nct06498479","lung-cancer","topotecan","nct05947851","b7h3","nct07728955"]},{"feedId":"lancet-oncology","title":"[News] Kenya agrees major cuts to cancer drug prices","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00481-X/fulltext","date":"2026-09-17","refs":["multiple-myeloma","burkitt-lymphoma","leukaemia","burkitt-leukaemia","non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma","jcog9801","nct07075328"]},{"feedId":"lancet-oncology","title":"[News] Toxic dust around the World Trade Center","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00482-1/fulltext","date":"2026-09-17","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA–Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01914","date":"2026-09-16","refs":["nct07095309","nct05954078","colorectal","nct06936774"]},{"feedId":"jco","title":"Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-01967","date":"2026-09-16","refs":[]},{"feedId":"jco","title":"Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01156","date":"2026-09-15","refs":[]},{"feedId":"jco","title":"Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00285","date":"2026-09-15","refs":["childrens-oncology-group","ewing-sarcoma"]},{"feedId":"jco","title":"Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00785","date":"2026-09-15","refs":[]},{"feedId":"jco","title":"Bridging the Gap: Precision Oncology for Cancers of Unknown Primary","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01847","date":"2026-09-14","refs":[]},{"feedId":"nejm","title":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2610229?af=R&rss=currentIssue","date":"2026-09-12","refs":["sclc","yl201","lung-cancer","platinum-etoposide"]},{"feedId":"lancet-oncology","title":"[Articles] Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00305-0/fulltext","date":"2026-09-11","refs":["lung-cancer"]},{"feedId":"jco","title":"Acknowledgment of Reviewers 2026","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01815","date":"2026-09-11","refs":[]},{"feedId":"jco","title":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00602","date":"2026-09-11","refs":["egf","trastuzumab-emtansine","breast-cancer","trastuzumab","nct06891833","nct05035745","nct06590246","gdf7"]},{"feedId":"lancet-oncology","title":"[News] Increased tobacco production and cigarette imports in Africa","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00461-4/fulltext","date":"2026-09-10","refs":[]},{"feedId":"jco","title":"Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00545","date":"2026-09-10","refs":["celmods","multiple-myeloma","cereblon"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small","date":"2026-09-09","refs":["nct05318573","sevabertinib","lung-cancer","nct05035745","lung-squamous-cell-carcinoma","nct06590246","nsclc","nct06745882"]},{"feedId":"jco","title":"Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-02181","date":"2026-09-09","refs":["pleural-mesothelioma","checkmate-743","mesothelioma","nct07381309","ipilimumab","nct05663775","nivolumab","relatlimab-nivolumab"]},{"feedId":"jco","title":"Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00769","date":"2026-09-09","refs":["nct06976944","nct04153734","pembrolizumab","nct05224141","nct06949111","sarcoma"]},{"feedId":"jco","title":"LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00451","date":"2026-09-09","refs":["dlbcl","high-grade-b-cell-lymphoma-myc-bcl2","nct05487170","non-hodgkin-lymphoma","bcl10","bcl11b","adult-t-cell-leukaemia-lymphoma","jcog9801"]},{"feedId":"jco","title":"Purple Blossoms","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00469","date":"2026-09-08","refs":[]},{"feedId":"lancet-oncology","title":"[Articles] Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00223-8/fulltext","date":"2026-09-07","refs":["ovarian","nct06976944","nct04153734","pembrolizumab","nct05224141","nct07381309","nct05035745","olaparib"]},{"feedId":"lancet-oncology","title":"[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00286-X/fulltext","date":"2026-09-07","refs":["multiple-myeloma","nct06771609","cyclophosphamide","dexamethasone","lenalidomide","daratumumab","bortezomib","nct05222971"]},{"feedId":"lancet-oncology","title":"[Perspectives] Sir Chris Hoy's Tour de 4 charity cycle ride returns","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00330-X/fulltext","date":"2026-09-06","refs":["prostate"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative","date":"2026-09-04","refs":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","egf"]},{"feedId":"lancet-oncology","title":"[Comment] Exercise oncology: from trials and guidelines to routine clinical care","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00386-4/fulltext","date":"2026-09-04","refs":["exercise-oncology"]},{"feedId":"lancet-oncology","title":"[Articles] An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00304-9/fulltext","date":"2026-09-04","refs":["androgen-deprivation","prostate","exercise-oncology"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 181–90","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00405-5/fulltext","date":"2026-09-03","refs":[]},{"feedId":"jco","title":"Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02974","date":"2026-09-03","refs":["cancer-of-unknown-primary","nct07381309","nct05744687","nct05281471","nct06463665","nct07290088","cupisco"]},{"feedId":"jco","title":"Bridging the Gap: Mounting Evidence for Metastasis-Directed Therapy in Oligometastatic Disease","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01339","date":"2026-09-02","refs":[]},{"feedId":"jco","title":"Bridging the Gap: Clinical Integration of Thrombopoietin Receptor Agonists in GI Cancer–Associated Chemotherapy-Induced Thrombocytopenia","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01447","date":"2026-09-01","refs":["nct07381309"]},{"feedId":"jco","title":"Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02659","date":"2026-08-28","refs":["nct05318573","lung-cancer","durvalumab","nct03800134"]},{"feedId":"lancet-oncology","title":"[News] Delays in cancer referrals and care lead to harm and missed diagnoses in England","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00443-2/fulltext","date":"2026-08-27","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00355","date":"2026-08-27","refs":["nct07683403","nct07535632","nct06992258","colorectal","bevacizumab-glioma","bevacizumab","nct06791512","nct07007767"]},{"feedId":"fda-oce","title":"FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma","date":"2026-08-26","refs":["pancreatic","revolution-medicines","urethral-adenocarcinoma","lung-adenocarcinoma","daraxonrasib","beone"]},{"feedId":"fda-oce","title":"FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction","date":"2026-08-25","refs":["oesophageal-adenocarcinoma","jazz","beone","urethral-adenocarcinoma","lung-adenocarcinoma","tislelizumab","nct07381309","zanidatamab"]},{"feedId":"jco","title":"Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02234","date":"2026-08-25","refs":["nct06949111"]},{"feedId":"jco","title":"Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-03080","date":"2026-08-24","refs":["rhabdomyosarcoma","fdg-pet"]},{"feedId":"lancet-oncology","title":"[News] Trump cuts childhood vaccine recommendations","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00433-X/fulltext","date":"2026-08-20","refs":[]},{"feedId":"lancet-oncology","title":"[News] Nigeria plans major expansion of radiotherapy capacity","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00434-1/fulltext","date":"2026-08-20","refs":["nct06949111"]},{"feedId":"jco","title":"Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02255","date":"2026-08-20","refs":["breast-her2-positive","breast-cancer","trastuzumab","nct06891833","pertuzumab","nct04514419","her2"]},{"feedId":"jco","title":"Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01944","date":"2026-08-17","refs":["nct07381309","nct05035745","nct06590246"]}]}